ITGA2B

Across TCGA pan-cancer cohorts, ITGA2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITGA2B data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITGA2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITGA2B expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where ITGA2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.297	0.534	<.001	61	view →
LSCC	DFS	Median	All	0.869	0.999	.003	38	view →
CCRCC	DFS	Quartile	III,IV	0.239	0.737	<.001	28	view →
HNSC	DFS	Median	II,III,IV	0.984	0.907	.006	12	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.424	.023	4	view →
LUAD	OS	Quartile	III,IV	0.668	1.000	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITGA2B–PDAC (DFS)

Open the PDAC breakdown →